Program
gumokimab
Its studies are mostly in Psoriasis · Spondylitis, Ankylosing, led by Akeso.
Furthest: phase 3, since Sep 27, 20236 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Akeso | 61 open or running | phase 3since Sep 27, 2023 | Feb 10, 2022 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 10, 2022First study: phase 2 study in Spondylitis, AnkylosingFirst studyNCT05467995 · 125 enrolled · China
- Jun 29, 2022Phase 1 study in PsoriasisNCT05504317 · 48 enrolled · China
- Sep 24, 2023Phase 2 study in PsoriasisNCT06061471 · 454 enrolled · China
- Sep 27, 2023Phase 3 study in PsoriasisNCT06066125 · 351 enrolled · China
- Mar 1, 2024Phase 3 study in Spondylitis, AnkylosingNCT06378697 · 510 enrolled · China
- Apr 21, 2025Phase 1 study in Healthy SubjectsNCT06947109 · 48 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06947109Healthy Subjects · China | 1 | Not yet recruiting | Jan 30, 2026 | 48 |
| NCT06378697Spondylitis, Ankylosing · China | 3 | Completed | Feb 19, 2025 | 510 |
| NCT06066125Psoriasis · China | 3 | Completed | Aug 19, 2024 | 351 |
| NCT06061471Psoriasis · China | 2 | Completed | Dec 11, 2024 | 454 |
| NCT05504317Psoriasis · China | 1 | Completed | Mar 2, 2021 | 48 |
| NCT05467995Spondylitis, Ankylosing · China | 2 | Completed | Apr 25, 2022 | 125 |
How it is read
Names in the registry
- “AK111”, 8 entries
Conditions, from the studies’ own filings
- Psoriasis, 3 studies
- Spondylitis, Ankylosing, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.